OCTYL 3,4-DIHYDROXYBENZOATE


Synonyms	3,4-Dihydroxy-Benzoic Acid Octyl Ester
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	BPRDKTKLZBOBGP-UHFFFAOYSA-N
Smiles	CCCCCCCCOC(=O)c1ccc(O)c(O)c1
InChI	InChI=1S/C15H22O4/c1-2-3-4-5-6-7-10-19-15(18)12-8-9-13(16)14(17)11-12/h8-9,11,16-17H,2-7,10H2,1H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H22O4
Molecular Weight	266.33
AlogP	4.35
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	9.0
Polar Surface Area	66.76
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	19.0

Assay Description	Organism	Bioactivity
Uncompetitive inhibition of Agaricus bisporus (mushroom) tyrosinase assessed as increase in Km and Vm without change in Km/Vm using L-DOPA as substrate at 50 uM by Line-weaver burk plot analysis	Agaricus bisporus	None
Irreversible inhibition of Agaricus bisporus (mushroom) tyrosinase assessed as remaining enzyme activity at >75 uM using L-DOPA as substrate by spectrophotometric analysis	Agaricus bisporus	None
Reversible inhibition of Agaricus bisporus (mushroom) tyrosinase assessed as remaining enzyme activity at <50 uM using L-DOPA as substrate by spectrophotometric analysis	Agaricus bisporus	None
Inhibition of Agaricus bisporus (mushroom) tyrosinase-catalyzed oxidation of L-DOPA substrate by spectrophotometric analysis	Agaricus bisporus	129000.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL117448
PubChem	10061460
SureChEMBL	SCHEMBL2937491

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).